Physician profile
Jesus Martinez
NPI 1194916882
$9,642.53
in general payments reported to CMS, 2019-2025
40 companies · $1,588 in 2025
The $1,588 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $205 · 2020: $327 · 2021: $864 · 2022: $2,043 · 2023: $1,627 · 2024: $2,989 · 2025: $1,588.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,193 · Travel and Lodging: $973 · Education: $37.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,193.41 |
| Travel and Lodging | $973.10 |
| Education | $37.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $1,519.76 | 2021-2024 | Vns Therapy |
| Abbvie INC. | $1,197.44 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $904.26 | 2021-2025 | |
| Sk Life Science, INC. | $590.20 | 2021-2025 | |
| Eisai INC. | $518.97 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $503.62 | 2019-2024 | Ultomiris, Soliris |
| Biogen, INC. | $410.74 | 2021-2025 | Vumerity, Tysabri |
| Ucb, INC. | $380.76 | 2020-2025 | Nayzilam, Briviact, Zilbrysq |
| Genentech USA, INC. | $347.27 | 2019-2025 | Ocrevus Zunovo, Ocrevus |
| Impel Pharmaceuticals INC. | $277.37 | 2022-2023 | Trudhesa |
| Neurocrine Biosciences, INC. | $267.55 | 2022-2025 | Ingrezza, Ongentys |
| Celgene Corporation | $252.09 | 2021-2025 | Zeposia |
| Medtronic, INC. | $221.57 | 2021-2024 | Activa PC |
| Lilly USA, LLC | $201.10 | 2022-2025 | Kisunla, Emgality, Reyvow |
| Argenx US, INC. | $185.59 | 2024-2025 | Vyvgart Hytrulo |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $178.03 | 2021-2025 | Vyepti |
| Pfizer INC. | $163.58 | 2023-2025 | |
| Emd Serono, INC. | $151.79 | 2019-2023 | Mavenclad |
| Biohaven Pharmaceutical Holding Company LTD. | $150.24 | 2022 | |
| Neurelis, INC. | $144.57 | 2022-2025 | Valtoco |
| Amgen INC. | $126.81 | 2021-2025 | Uplizna |
| Janssen Pharmaceuticals, INC | $121.85 | 2022 | |
| Medtronic Vascular, INC. | $115.00 | 2020 | |
| Tanabe Pharma America, INC. | $87.64 | 2021-2024 | |
| Teva Pharmaceuticals USA, INC. | $84.91 | 2022-2023 | Austedo Xr |
| Amneal Pharmaceuticals LLC | $82.49 | 2022-2025 | Crexont |
| Grt US Holding, INC. | $81.38 | 2021-2022 | |
| Acadia Pharmaceuticals INC | $62.43 | 2022-2025 | Daybue |
| Ge Healthcare | $56.20 | 2020-2021 | |
| C2n Diagnostics, LLC | $38.73 | 2025 | Precivityad2 |
| Abbott Laboratories | $37.09 | 2021-2025 | Freestyle Libre 3 |
| Allergan, INC. | $26.02 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $23.43 | 2023 | Aptiom |
| Bioventus LLC | $21.40 | 2020 | |
| Tg Therapeutics, INC. | $20.06 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.96 | 2025 | |
| Insulet Corporation | $18.88 | 2021 | |
| Averitas Pharma INC. | $18.39 | 2024 | Qutenza |
| Sunovion Pharmaceuticals INC. | $18.01 | 2022 | |
| Csl Behring | $16.35 | 2024 | Hizentra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jesus Martinez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.